Observational studyPloS one2026
A natural history study of Chinese individuals with Duchenne muscular dystrophy: Results from 2 years of follow-up and beyond.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03760029 (A NATURAL HISTORY STUDY IN CHINESE MALE PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A natural history study in chinese male patients with duchenne muscular dystrophy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesNatural history studies in Duchenne muscular dystrophy (DMD) can help to elucidate the trajectory of the disease, understand the importance of clinical milestones, and identify endpoints for clinical trials. We present data from a natural history study of DMD in Chinese individuals with a follow-up of up to 30 months.
methodsThis was a multicenter, prospective, single-cohort study in Chinese boys of any age with a confirmed diagnosis of DMD. Participants were allocated into one of three groups: Group 1 (ambulatory, < 6 years old); Group 2 (ambulatory, ≥ 6 years old); and Group 3 (non-ambulatory, any age). Endpoints included time to life-altering clinical milestones, North Star Ambulatory Assessment (NSAA; Groups 1 and 2), Performance of Upper Limb 2.0 (PUL2.0; Groups 2 and 3), pulmonary function (Groups 2 and 3), left ventricular ejection fraction (LVEF; Groups 2 and 3), and quality of life endpoints.
results312 participants were enrolled (Group 1, n = 99; Group 2, n = 177; Group 3, n = 36). Mean (SD) age at baseline in the total study population was 7.9 (3.4) years. Median (95% confidence interval) age at failure to walk in the total study population was 13.1 (12.5-14.1) years. Up to 30 months, NSAA total score deteriorated in Group 2 with no decline in Group 1. PUL 2.0 score declined in both Groups 2 and 3. Pulmonary function decreased in Groups 2 and 3 but to a greater extent in Group 3. Changes in LVEF were minimal. Quality of life deteriorated over time, particularly in Group 3. DISCUSSION: These data extend the 1-year findings from the same study and demonstrate the progression of DMD in Chinese individuals of differing age and ambulatory status. REGISTRATION INFORMATION: ClinicalTrials.gov identifier: NCT03760029.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.